The Role Of Somatic Mutations In CCCTC-binding Factor (CTCF) Binding Sites In Cancer
Funder
National Health and Medical Research Council
Funding Amount
$371,114.00
Summary
The three dimensional organisation of genomic DNA has been recognised to play a crucial role in maintaining the stability and function of human cells. In cancer this organisation is often perturbed as a result of mutations to proteins that govern this process. This project will examine how mutations in the DNA may potentially alter the three dimensional organisation of cancer genomes and will identify links between these mutations with cancer development and patient prognosis.
Targeting Cancer-initiating Cells With DNA Methyltransferase Inhibitors: Single-cell Analysis To Decipher Molecular Mechanisms And Improve Efficacy.
Funder
National Health and Medical Research Council
Funding Amount
$175,000.00
Summary
Certain cancer cells, termed cancer-initiating cells (CICs), have special properties allowing them to drive cancer growth and disease progression. These cells are particularly sensitive to low-dose treatment with drugs called DNA methyltransferase inhibitors. Using cutting-edge "single-cell" technologies this project will determine how these drugs target CICs and identify new ways to increase treatment efficacy. This work will identify new clinical opportunities for prevention of cancer relapse.
Investigation Of DUSP5 As A Novel Tumour Suppressor Gene In Colon Cancer
Funder
National Health and Medical Research Council
Funding Amount
$578,268.00
Summary
Colon cancer is the second leading cause of cancer related death in Australia. Understanding the genetic causes of this disease are essential to developing new treatment strategies. The goal of this study is to understand the role of the DUSP5 gene in colon cancer. The findings of this study has the potential to further our understanding of how colon cancers arise and for identifying patients likely to respond to specific existing treatments.
Understanding Cancer Development And Metastasis Through Regulation Of Cell Plasticity
Funder
National Health and Medical Research Council
Funding Amount
$773,103.00
Summary
I aim to understand how cancer cells switch between non-aggressive and aggressive cell states, and to determine how these processes contribute to cancer development and progression. In determining the factors that drive these processes I aim to discover novel strategies for deriving effective therapies for patients with aggressive and advanced-stage cancer.
Targeting Homeobox Genes In Acute Myeloid Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$658,739.00
Summary
Acute myeloid leukaemia (AML) is a common blood cancer with dire clinical prognosis due to a lack of targeted molecular therapies. In this proposal we will identify new ways of targeting transcription factor proteins that are overexpressed in AML and promote leukaemia by repressing normal cellular growth controls. This may lead to novel methods to target leukaemic stem cells to specifically eliminate myeloid leukemia
Mechanistic Basis Of AP-1-regulated Gene Expression During Colorectal Cancer Progression
Funder
National Health and Medical Research Council
Funding Amount
$597,802.00
Summary
The spread of colorectal cancers in the body poses a major clinical problem for which current treatment options are inadequate. This project aims to unravel how a specific DNA-binding protein regulates the expression of genes involved in the spread of these cancers. The research is expected to provide a better mechanistic understanding of how disease progression occurs and to identify novel strategies to treat aggressive tumours.
Wnt-5a Signalling - A Novel Therapy For Triple Negative And Tamoxifen Resistant Breast Cancer Patients
Funder
National Health and Medical Research Council
Funding Amount
$330,534.00
Summary
Breast cancer is the most common cancer in women. Commonly used drugs target the estrogen receptor (ER). However, one third of breast cancer patients lack ER, and do not respond to treatment. Cancers that lack ER also lack a gene called Wnt5a, which is linked to better prognosis. We have shown that fixing Wnt5a can restore ER allowing cells to respond to Tamoxifen. We would now test this in animals, in the hope of developing a new drug for breast cancer patients currently with limited options.
I am a cancer biologist determining the mechanisms controlling growth and proliferation of cancer cells and use transgenic models of malignancy and genetic approaches to identify new therapies for targeting growth control in the treatment of cancer.
Epigenetics describes how genes can be turned off or on without changing the DNA sequence. Epigenetics plays a major role in cancer development. In this proposal we are investigating a novel hypothesis that in cancer a similar mechanism to imprinting USING NON-CODING RNA is triggered and this promotes the suppression of clusters of genes. The results from this proposal will have major implications to our understanding of gene regulation in cancer and will have important therapeutic value for can ....Epigenetics describes how genes can be turned off or on without changing the DNA sequence. Epigenetics plays a major role in cancer development. In this proposal we are investigating a novel hypothesis that in cancer a similar mechanism to imprinting USING NON-CODING RNA is triggered and this promotes the suppression of clusters of genes. The results from this proposal will have major implications to our understanding of gene regulation in cancer and will have important therapeutic value for cancer treatment.Read moreRead less